Compare ARLO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | EVO |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | N/A |
| Metric | ARLO | EVO |
|---|---|---|
| Price | $13.49 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $24.00 | $7.00 |
| AVG Volume (30 Days) | ★ 1.6M | 123.2K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.88 | N/A |
| Revenue Next Year | $9.23 | $7.13 |
| P/E Ratio | $96.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $2.40 |
| 52 Week High | $19.94 | $4.80 |
| Indicator | ARLO | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 22.23 |
| Support Level | $13.09 | N/A |
| Resistance Level | $14.34 | $3.78 |
| Average True Range (ATR) | 0.72 | 0.10 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 41.39 | 0.18 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.